[
  {
    "sentence": "Figure 3B shows the correlation between anti–SARS-CoV-2 antibody titers and neutralizing activity, demarcating responses into quadrants based on test results.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "For individuals (patients and healthy controls) with negative antibody titers and negative neutralizing activity (n = 60; group Q1 in Fig. 3B), the median antibody titer was 5.4 AU/mL (IQR 1.8–12) with median percentage inhibition 2.2% (IQR 0–6.5).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "For individuals with positive antibody titers but negative neutralizing activity (n = 27; group Q2 in Fig. 3B), the median antibody titer was 101.7 AU/mL (IQR 78–150.4) with median percentage inhibition 17.5% (IQR 9.9–24.3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "For individuals with positive antibody titers and positive neutralizing activity (n = 44; group Q3 in Fig. 3B), the median antibody titer was 1,891 AU/mL (IQR 557.2–8,733) with median percentage inhibition 84.9% (IQR 51.8–95.2).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "For individuals with positive antibody titers but negative neutralizing activity after one vaccine (n = 23; group Q2 in Fig. 3B), the median antibody titer after receiving a second vaccine increased to 2,121 AU/mL (IQR 991.4–4,680), an antibody level with a high likelihood of adequate neutralizing capacity (i.e., antibody titer ≥500).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In contrast, for individuals with negative antibody titers and negative neutralizing activity after one vaccine (n = 45; group Q1 in Fig. 3B), the median antibody titer after receiving a second vaccine increased incrementally to 15.7 AU/mL (IQR 2.1–345.6), an antibody level with low likelihood of adequate neutralizing capacity (i.e., antibody titer <50).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Of the patients in the Q1 subgroup who failed to mount positive antibody titers after receiving a second vaccine (n = 29; Fig. 3B), perivaccine treatments included anti-CD19/CD20–directed therapies (n = 11), PI3K inhibitors (n = 5), anti-CD38–directed therapy (n = 4), BTK inhibitors (n = 3), anti-BCMA–directed therapies (n = 2), venetoclax (n = 2), lenalidomide (n = 1), and prednisone (n = 1).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  }
]